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Abstract
Introduction: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer that is diagnosed in
approximately 15% of all human breast cancer (BrCa) patients. Currently, no targeted therapies exist for this
subtype of BrCa and prognosis remains poor. Our laboratory has previously identified a proliferation/DNA repair/
cell cycle gene signature (Tag signature) that is characteristic of human TNBC. We hypothesize that targeting the
dysregulated biological networks in the Tag gene signature will lead to the identification of improved combination
therapies for TNBC.
Methods: Cross-species genomic analysis was used to identify human breast cancer cell lines that express the Tag
signature. Knock-down of the up-regulated genes in the Tag signature by siRNA identified several genes that are
critical for TNBC cell growth. Small molecule inhibitors to two of these genes were analyzed, alone and in
combination, for their effects on cell proliferation, cell cycle, and apoptosis in vitro and tumor growth in vivo.
Synergy between the two drugs was analyzed by the Chou-Talalay method.
Results: A custom siRNA screen was used to identify targets within the Tag signature that are critical for growth of
TNBC cells. Ribonucleotide reductase 1 and 2 (RRM1 and 2) and checkpoint kinase 1 (CHK1) were found to be
critical targets for TNBC cell survival. Combination therapy, to simultaneously attenuate cell cycle checkpoint
control through inhibition of CHK1 while inducing DNA damage with gemcitabine, improved therapeutic efficacy
in vitro and in xenograft models of TNBC.
Conclusions: This combination therapy may have translational value for patients with TNBC and improve
therapeutic response for this aggressive form of breast cancer.
Introduction
Triple negative breast cancer (TNBC) is an aggressive and
heterogeneous subtype of breast cancer defined by the
absence of estrogen (ER) and progesterone (PR) steroid
hormone receptor expression and lacking high expression
and/or amplification of HER2/ERBB2. Although TNBC
represents only 10% to 15% of breast cancer diagnoses, it
disproportionately affects pre-menopausal women and
African-American women and is associated with poor
prognosis [1]. Due to the absence of hormone receptor
expression and lack of human epidermal growth factor
receptor 2 (HER2) overexpression, no targeted therapies
exist for TNBC, which limits treatment to standard che-
motherapy [2]. Paradoxically, women with TNBC have a
significantly higher rate of pathologic complete response
(pCR) to standard chemotherapy compared to other types
of breast cancer [3,4]. Yet those TNBC patients who do
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not undergo a pCR generally experience recurrence within
the first three years and poor overall survival due to an
increased incidence of distant node, lung, and brain metas-
tases [5]. Thus, identification of drugs that target specific
molecular features of TNBC and the use of improved pre-
clinical models for this disease are important research
priorities.
Mutations in p53 and loss of function of the pRb path-
way are found in the majority of TNBCs. These muta-
tions lead to the dysregulation of many genes, including
genes that regulate the cell cycle and apoptosis, and may
account for the particularly aggressive properties of this
form of breast cancer [1]. More than 44% of TNBCs have
been found to harbor p53 mutations [1], whereas loss of
Rb function occurs in at least 70% of TNBCs [6,7]. In
order to identify potential molecular targets for TNBC
related to loss of the critical tumor suppressor functions
of p53 and pRb, we hypothesized that identification of a
gene expression signature based upon the expression of
an oncoprotein whose mechanism of transformation
results in the inhibition of p53 and Rb function would be
highly relevant to human TNBC. We previously identi-
fied a common gene expression signature (Tag signature)
comprised of approximately 120 named genes based
upon the loss of p53 and Rb functions in several trans-
genic mouse models of epithelial cancers (including the
C3(1)/Tag model of mammary cancer) where the func-
tions of these two tumor suppressor genes are abrogated
by the expression of the SV40 T-antigen (Tag) oncopro-
tein [8]. Tag is known to bind to and functionally inacti-
vate both p53 and the pRb family of proteins, thus
providing a means to simultaneously inhibit the tumor
suppressor activities of these proteins. The molecular
relevance of Tag-induced mammary cancer arising in the
C3(1)/Tag model to human TNBC has been clearly
demonstrated through gene expression profiling. It
revealed that the C3(1)/Tag transgenic model is the
genetically-engineered mouse model of mammary cancer
most closely related to human TNBC [9] and shares
many other important biological features of the human
disease [8-10].
Further analyses revealed that the Tag signature is
highly represented in human TNBC and could distin-
guish triple negative from other forms of breast cancer
[8]. Contained within the Tag signature are genetic nodes
related to the functions of p53, pRb, MYC, and genes
regulating apoptosis [8]. The 120-gene signature contains
genes involved in DNA metabolism and replication
(Dhfr, Top2a, Tyms), DNA repair (Claspin, Rrm1, Pola1),
chromosome maintenance (Plk4, Mcm genes), cell cycle
regulation (Pk2, Chk1), cell replication and proliferation
(Cdc28, Ki67, Pcna), microtubule stabilization (Kif11,
Stmn1), and apoptosis (Birc5, Casp2), suggesting that the
expression of genes contained within this signature could
be vital for the survival and maintenance of this aggres-
sive form of human breast cancer.
We hypothesized that some of the dysregulated genes
contained in the Tag signature are essential for the survi-
val of TNBC cells either alone or in combination. In
order to test this hypothesis, the up-regulated genes
within the Tag signature were knocked-down in human
TNBC cells using a custom siRNA library. This screen
identified the two subunits of ribonucleotide reductase,
RRM1 and RRM2, and the checkpoint kinase CHK1, as
particularly sensitive targets resulting in the reduced sur-
vival of TNBC cells. These results were further validated
both in vitro and in vivo using gemcitabine, an inhibitor
of RRM1 and RRM2, and UCN-01 and AZD 7762, inhibi-
tors of CHK1, using several human triple negative cell
lines and the C3(1)/Tag transgenic model of TNBC.
Since CHK1 activation results in cell cycle arrest that is
necessary for DNA repair, and RRM1 and RRM2 are cri-
tical for DNA synthesis and repair, we further hypothe-
sized and demonstrated that inhibiting CHK1, RRM1 and
RRM2 through combined treatment with gemcitabine
and UCN-01 resulted in greater therapeutic efficacy than
either agent alone. These results demonstrate that a gene
signature identified through cross-species analysis of rele-
vant molecular pathways can be useful for the identifica-
tion of targets for TNBC.
Materials and methods
Reagents
For in vitro assays, therapeutic agents were purchased as
noted. UCN-01 and gemcitabine hydrochloride, were
purchased from Sigma-Aldrich (St. Louis, MO, USA).
The specific CHK1 inhibitor, AZD 7762, was provided
by the Helen Piwinica-Worms laboratory (Washington
University in St. Louis, MO, USA) [11]. All therapeutic
agents were dissolved in dimethyl sulfoxide (DMSO),
aliquoted, and stored at -20°C.
Cell culture and drug treatment
Human breast cancer cell lines MDA-MB-231, Hs578T,
SUM 159, HCC1187, BT-549 and MCF-7 were purchased
from the American Type Culture Collection (Manassas,
VA, USA). The mouse mammary tumor cell line, M6, was
derived from a C3(1)TAg mouse mammary tumor as
reported previously [12]. Growth media for MDA-MB-231
cells (RPMI medium 1640) and M6 cells ((D)MEM (high
glucose)) were supplemented with 5%(v/v) fetal bovine
serum (FBS), penicillin-streptomycin and MEM sodium
pyruvate (100 mM). Hs578T cells were cultured in (D)
MEM high glucose supplemented with 10% FBS, penicil-
lin-streptomycin and MEM sodium pyruvate solution 100
mM. SUM 159 cells were cultured in Ham’s F-12 medium
supplemented with 5% FBS, 5 μg/mL recombinant human
insulin, 1 μg/mL hydrocortisone, and 10 mM HEPES.
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BT-549 cells were cultured with RPMI-1640 medium sup-
plemented with 10% FBS and 0.852 μg/mL recombinant
human insulin. HCC1187 cells were cultured in RPMI-
1640 media supplemented with 10% FBS and penicillin-
streptomycin. MCF-7 cells were cultured in (D)MEM
(high glucose) supplemented with 10% FBS, penicillin-
streptomycin, MEM sodium pyruvate solution 100 mM,
and MEM non- essential amino acids. Normal human
breast epithelial cells, M98040 and M99005, were provided
by Ofelia Olivero (National Institutes of Health, Bethesda
MD, USA) and cultured as reported [13]. MCF10A cells
(M-I) were provided by Lalage Wakefield (National Insti-
tutes of Health) and cultured as described [14]. All cell
culture reagents were purchased from Invitrogen
(Gaithersburg, MD, USA).
Microarray data
Four microarray data sets were analyzed. GEMII cDNA
array data profiles of SV40T/t-antigen mouse mammary
tumors and normal mammary tissue (FVB background),
which were used to derive the SV40-Tag signature (Tag
signature), are described elsewhere [8]. The human
MDA-MB-231 breast cancer cell line and M98040/
M99005 epithelial cells were profiled on HG-U133Plus2
chips, Affymetrix (Santa Clara, CA, USA) and processed
with GC-RMA and quantile normalization [15]. The data
for the M6 mouse breast cancer cell line, other C3(1)/
Tag mouse mammary tumors and normal mammary tis-
sue samples (FVB background) were generated using
Affymetrix MOE430A arrays and processed with RMA
and quantile normalization [15]. Publicly available data
for 51 human breast cancer cell lines were obtained from
Neve et al. [16]. The SV40 T/t-antigen-specific gene sig-
nature was mapped between platforms and/or species
using Entrez Gene ID and JAX homology with the anno-
tation provided in the mAdb database [17]. Multiple
array probes mapping to the same Entrez IDs were
reduced to single probes with the highest median signal
across all the samples. Prior to integration of the four
data sets each gene expression was standardized to the
distribution of the mean of zero and unit standard devia-
tion (z-score transformation). The analyses were per-
formed with R statistical programming [18] and the
Bioconductor affy and gcrma packages [19].
siRNA library and screen
A custom-designed gene library of 108 pools of four
siRNA oligos [see Additional file 1, Table S1] was used
for the siRNA screen (siGenome, Dharmacon, Lafayette
CO, USA). In addition to the siRNA library wells, each
plate contained three replica wells with negative controls
(Dharmacon) (pool of non-targeting siRNA (NTS) and
cyclophilin B siRNA) and positive controls (Plk1 siRNA
(Dharmacon) and All-Star Cell Death siRNA (Qiagen,
Valencia, CA, USA). The Tag siRNA library consists of
siRNA oligo pools, 4 oligos/pool, for each of the 80 up-
regulated genes in the Tag signature. The library also
contains 28 genes that have recently been associated
with TNBC [20,21].
siRNA transfections
Transfections were performed by pre-complexing siRNA
(1 pmol) with Oligofectamine lipid transfection reagent
(Invitrogen) in serum-free media (RPMI for MB-MDA-
231, (D)MEM for HS578T or (D)MEMF12 for MCF10A)
in individual wells for 30 minutes at room temperature
(RT). Cells were added in media supplemented with 2x
FBS resulting in final concentrations of 10 nM siRNA
and 5% FBS for MB-MDA-231 (50 nM and 10% FBS for
HS578T and MCF10A). The cell/siRNA mix was incu-
bated at RT for 45 minutes before being placed at 37 °C
in a humidified atmosphere containing 5% CO2 for the
times indicated. Primary siRNA library screens were per-
formed in 96 well plates (utilizing the interior 60 wells
only to reduce data variation as a result of evaporation at
the edges of the plate), incubated for 72 hours and ana-
lyzed for proliferation changes. RNA, for quantitative
real-time PCR, was isolated from 12 well plates 24 hours
post-transfection. Protein studies, for immunoblot analy-
sis, were performed in 6-well dishes and harvested 48
hours post-transfection.
The mean absorbance values per gene target per plate
were normalized using the mean value for non-targeting
siRNA (NTS) transfected cells. Z-scores were calculated
relative to the plate mean and standard deviation.
For de-convolution studies, four siRNAs targeting a
given gene were evaluated individually, each used at a
concentration of 10 nM, and compared to non-targeted
siRNA #2 (Dharmacon).
Proliferation assay
Cells were counted and plated in 96-well cell culture
plates. Twenty-four hours later cells were treated with
therapeutic agents as described. At time points indi-
cated, cell proliferation was assayed with CellTiter 96R
Aqueous Non-Radioactive Cell Proliferation Assay fol-
lowing manufacturers protocol (Promega, Madison, WI,
USA). Data points represent an average of three samples
per treatment and experiments were repeated at least
three times.
mRNA gene expression analysis
RNA was extracted from cells using TRIzol reagent (Invi-
trogen) and purified using the RNeasy Mini kit (Qiagen)
according to the manufacturer’s instructions. RT-PCR was
performed on 500 ng RNA using TaqMan reverse tran-
scription reagents (Applied Biosystems, Carlsbad, CA).
Quantitative real time PCR was performed using iQSybr
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Green Supermix (BioRad, Hercules, CA,) and quantified
using an iCycler Real Time PCR unit (BioRad) using PPIA
as an internal control. The primers used for each gene are
as follows: RRM1 (F: AAG AGC AGC GTG CCA GAG
AT, R: ACA CAT CAA AGA CCA GTC CTG ATT AG)
[22], RRM2 (F: GCA GCA AGC GAT GG CAT AGT, R:
GGG CTT CTG TAA TCT GAA CTT C) [23], CHK1 (F:
AGC GGT GGT CAA AAG AAT G, R: TGT CTG CAT
CCA ATT TGG TAA), and PPIA (F: TTC ATC TGC
ACT GCC AAG AC, R: TCG AGT TGT CCA CAG TCA
GC).
Combination index calculations
CompuSyn (ComboSyn, Inc., Paramus, NJ) was used to
assess the interaction of the drugs in combination for
synergy/additivity/antagonism to determine the combina-
tion index (CI) using the Chou-Talalay method [24]. Cell
proliferation assay data (MTS assays) were expressed as
the fraction of cells inhibited by the individual drugs or
the combination compared to the vehicle (DMSO)-treated
control cells; these data were used to determine CI [see
Additional file 2, Table S2]. When the CI is <1, the combi-
nation is synergistic, when the CI is =1 the combination is
additive, and when the CI is >1 the combination is consid-
ered antagonistic.
Protein analysis
Cells were washed in PBS and lysed for protein in radio-
immunoprecipitation assay (RIPA) buffer. Protein was
quantified using a BCA protein assay kit (Pierce, Rock-
ford, IL), separated by polyacrylamide gel electrophoresis
and transferred to nitrocellulose membrane (Invitrogen)
for detection using the following primary antibodies:
RRM1 (3388; Cell Signal, Danvers, MA, USA), RRM2
(10846; Santa Cruz, Santa Cruz, CA, USA), b-tubublin
(RB-9249; Thermo Scientific, Rockford, IL, USA ), Phos-
pho-gamma H2AX (2577; Cell Signaling Technology,
Beverly, MA), Cyclin A (Rb-1548; Neomarkers, Free-
mont, CA, USA) b-actin (A1978; Sigma), phospho Chk1
ser-345 (Rb-2348; Cell Signaling Technology), Chk1
(Ms-2360; Cell Signaling Technology).
Cell cycle analysis
Actively growing MDA-MB-231 cells were pulsed with
10 μg/mL bromodeoxyuridine (BrdU) (BD Pharmingen,
San Diego, CA, USA) for one hour. Cells were trypsi-
nized, washed and fixed in 70% ethanol. DNA was dena-
tured and cells were incubated with anti-BrdU-FITC (BD
Pharmigen) for one hour. Cells were washed and re-sus-
pended in 10 μg/mL propidium iodide (PI) solution
(Sigma-Aldrich) to detect cell viability. Cells were sorted
by flow cytometry, exciting at 488 nm and measuring
BrdU-FITC with a 514 nm filter and PI with a 699 filter.
Data points represent an average of at least three samples
and the experiment was repeated twice.
Apoptosis assay
Early and late apoptosis was detected in cells labeled with
Annexin V- fluorescein isothiocyanate (FITC) and 7-
amino-actinomycin D (7-AAD, eBioscience, San Diego,
CA, USA). Briefly, cells were treated with the therapeutic
agents indicated. At 48 hours, media was collected to
retain floating cells and adherent cells were washed in
PBS and trypsinized. Cell fractions were pooled, centri-
fuged, washed in PBS, and re-suspended in Annexin V
binding buffer. Cells were incubated with Annexin V for
20 minutes, washed in PBS and re-suspended in Annexin
V binding buffer. 7-AAD was added immediately prior to
sorting by flow cytometry, excited at 488 nm with
Annexin V-FITC levels measured with a 514 nm filter
and 7-AAD with a 699 filter. Cells undergoing early
apoptosis were detected by plasma membrane exclusion
of viability dye 7-AAD and inclusion of Annexin-V. Late
stage apoptosis was detected by plasma membrane inclu-
sion of both 7-AAD and Annexin-V. Data points repre-
sent the average of four samples per treatment and the
experiment was repeated twice.
Caspase 3/7 Assay
Apoptosis was measured by Caspase 3/7 activation
48 hours after drug treatment. Caspase 3/7 substrate
100 μl (Caspase-Glo 3/7 Assay, Promega) was added to
the cells for one hour and luminescence was measured by
a Glomax luminometer using the standard Promega
protocol.
In vivo drug studies
Animal studies were approved and performed in accor-
dance with the National Institutes of Health Intramural
Animal Care and Use Program. Primary C3(1)/Tag mam-
mary tumors or MDA-MB-231 xenograft tumors were
isolated and prepared into 1 mm3 fragments. Tissue frag-
ments were implanted into the mammary fat pad (#4) of
female SCID/NCr mice (BALB/c background) from the
National Cancer Institute Animal Production Program
(Frederick, MD, USA), n = 8/cohort. Drug treatment was
initiated once tumors reached 125 mm3. Tumor size was
monitored bi-weekly using caliper measurements (in
millimeters) in two dimensions (length and width with
tumor volume = (length × (width)2/2. For C3(1)Tag
tumor bearing mice, gemcitabine (20 mg/kg) was deliv-
ered by intraperotineal (IP) injection on an every four
days for three treatments (Q4Dx3) schedule. UCN-01
(4.5 mg/kg) was delivered by intravenous (IV) injection
on a Q4x3 schedule with delivery scheduled twice per
day, six hours apart (Q6Hx2) schedule. Mice treated with
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single or combination therapy received gemcitabine (or
IP vehicle) first followed eight hours later by the first
UCN-01 (or IV vehicle) treatment. For MDA-MB-231
tumor bearing mice, gemcitabine (5 mg/kg) and UCN-01
(6 mg/kg) were delivered as noted above except that
UCN-01 (or IV vehicle) was first delivered 24 hours after
gemcitabine (or IP vehicle) rather than eight hours later.
Results
Triple-negative breast cancer cells express the Tag
signature
As previously reported, mammary tumors from C3(1)/
Tag transgenic mice express a genetic signature that is
highly represented in TNBCs [8]. In order to identify
human breast cancer cell lines that are enriched for the
Tag signature and that could be useful for determining
the biological effects of knocking-down the expression of
those genes in a preclinical model, gene expression data
from the 51 breast cancer cell lines reported by Neve
et al. [16] were analyzed for expression of the Tag signa-
ture. Additionally, gene expression profiles were also gen-
erated from RNA extracted from C3(1)/Tag mammary
tumors, normal mammary tissue from FVB/N mice, M6
cells (a cell line derived from C3(1)/Tag mammary
tumors) [12], and normal human breast epithelial cells
M98040 and M99005 [13]. Mouse and human gene
expression data were integrated and analyzed by hier-
archical clustering using Z-score transformed expression
values within each microarray dataset, the one minus un-
centered correlation distance metric and complete link-
age (GEO accession numbers: GSE25487 and GSE25488)
(Figure 1). As predicted, C3(1)/Tag mammary tumors
and M6 cells express the Tag signature whereas normal
human breast epithelial cells and normal mammary tis-
sue from FVB mice do not share expression of the Tag
signature. Of the human breast cancer cell lines analyzed,
the TNBC MDA-MB-231 cells most robustly expressed
the Tag signature as evidenced by the tight clustering of
these cells with Tag mammary tumors and the M6 cell
line (Figure 1). For this reason, the MDA-MB-231 cell
line was subsequently chosen as the human breast cancer
model for comparative studies in this manuscript. The
MDA-MB-231 cell line (MDA-MB-231 NIH) used in this
study was also analyzed by microarray and shown to con-
tain an expression signature quite similar to that as
originally reported by Neve et al. [16].
Identification of genes critical for proliferation of
MDA-MB-231 cells using a siRNA-based screen
To identify genes within the Tag signature whose
expression is critical for TNBC tumor survival and
growth, a custom siRNA library was designed to target
the 80 up-regulated genes contained in the Tag
signature [see Additional file 1, Table S1]. Twenty-eight
additional genes were also included in the siRNA library
based upon genetic relevance to TNBC and elevated
RNA expression in M6 cells and C3(1)/Tag tumors [see
Additional file 1, Table S1]. MDA-MB-231 cells were
reverse-transfected with the Tag siRNA library and
assayed for changes in proliferation 72 hours later [see
Additional file 1, Table S1; Figure 2A]. Out of 108 genes
targeted by siRNA, the knockdown of six genes signifi-
cantly inhibited cell growth as compared to cells trans-
fected with a pool of non-targeting siRNA oligo controls
(NTS) (Figure 2A). These six genes are RRM1, RRM2,
CHK1, TPX2, Anillin (ANLN), and kinesin-related mito-
tic motor protein (KIF11) (Table 1). Two other human
cell lines Hs578T, a TNBC cell line, and MCF10A, a
non-tumorigenic mammary cell line considered to exhi-
bit characteristics of normal mammary epithelial cells,
were also screened using the custom siRNA library. The
same six genes identified as critical to the growth of
MDA-MB-231 cells also significantly inhibited prolifera-
tion of the TNBC cell line HS578T [see Additional
file 1, Table S1; Table 1]. However, while siRNAs for
ANLN, TPX2 and KIF11 significantly inhibited MCF10A
cell proliferation, knock-down of RRM1, RRM2 and
CHK1 did not [see Additional file 1, Table S1; Table 1].
These findings suggest that RRM1, RRM2 and CHK1 are
selectively important for the TNBC cells, whereas
ANLN, TPX2, and KIF11 may be important to cellular
proliferation, but are not specific to triple negative
breast tumorigenesis. In this study, we therefore focused
on RRM1, RRM2 and CHK1 as targets for TNBC.
To confirm that the effect of pooled siRNA oligos was
specific, the pooled siRNA oligos for RRM1, RRM2, and
CHK1 genes were de-convoluted and each of the four indi-
vidual siRNAs was reverse-transfected into MDA-MB-231
cells and assayed for inhibition of proliferation (Figure 2B).
In comparison to a non-targeting control siRNA (NT#2)
at 100% growth, the four siRNA oligos for RRM1 and
RRM2 individually resulted in a 30% to 50% inhibition of
proliferation. Those for CHK1 individually inhibited prolif-
eration by 12% to 60%. The individual siRNA oligos for
RRM1, RRM2 and CHK1 produced a marked reduction in
gene (Figure 2C) and protein expression (Figure 2D). To
further confirm that CHK1 was not selected through off
target effects, MDA-MB-231 cells were transfected with
pooled siRNAs from another commercial source (Qiagen)
and assayed for their effects on proliferation (Figure 2E).
Cell proliferation was significantly inhibited by siRNA
silencing of CHK1 using these oligos. De-convolution of
this second siRNA pool demonstrated that all four of these
siRNA oligos significantly inhibited proliferation by at least
40% and reduced CHK1 RNA (Figure 2F) and protein
(Figure 2G) expression.
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Figure 1 Gene expression profile for the SV40/Tag signature across human breast cancer cell lines. Triple negative MDA-MB-231 cells
express a genetic profile for the SV40/Tag signature similar to C3(1)/Tag tumors. Two-way hierarchical clustering uses z-score transformed
expression values within each microarray dataset, one minus un-centered correlation distance metric and complete linkage. The colored bar
classifies the 51 cell lines from Neve et al. [16] and new samples into breast cancer subtypes adopted from Neve et al. [16]: Luminal (blue), Basal
A (red), claudin-low (orange), and normal-like (green). MB-MDA-231 cells (red box) cluster closely with C3(1)/Tag tumors and M6 cell line (blue
box). Other triple negative cell lines HCC 1187, SUM 159, and BT-549 are also highlighted (green boxes).
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Figure 2 siRNA screen for genes that promote proliferation of MDA-MB-231 cells identify CHK1, RRM1 and RRM2 as top-hits. (A)
Effects on proliferation by gene knockdown with the custom siRNA library. Data are shown as a z-score distribution from the mean. (B) Percent
change (from non-targeting siRNA (NTS) control) in proliferation of cells due to knock-down of expression by individual siRNA oligos for the
genes noted. Q-RT-PCR determination of reduced RNA (C) and protein (D) expression for CHK1, RRMI, and RRM2 for individual siRNA oligos. (E)
Percent growth of cells due to expression of Qiagen CHK1-siRNA. Gene (F) and protein (G) expression for CHK1 is suppressed in cells that are
transfected with individual Qiagen CHK1-siRNAs. Graphs shown are representative of 3 repeated experiments.
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Combination therapy with UCN-01 and gemcitabine
induces DNA damage and apoptosis in triple negative
breast cancer cell lines
Identification of RRM1, RRM2, and CHK1 in the siRNA
screen as critical genes for proliferation of MDA-MB-231
cells suggests that these genes may be effective therapeu-
tic targets for TNBC. Because RRM1 and RRM2 com-
prise the two subunits of ribonucleotide reductase, an
enzyme essential for maintaining adequate levels of
dCTPS for DNA synthesis and DNA repair, and CHK1
inhibits cell cycle progression to allow for adequate DNA
damage repair [25], we hypothesized that the combined
inhibition of all three proteins together could synergize
and enhance the inhibitory effects on cell proliferation
observed with each target individually. To address this
question, we treated the human MDA-MB-231 and
mouse M6 (derived from a C3(1)/Tag mammary tumor)
TNBC cell lines either alone or in combination with
gemcitabine, a drug that inhibits ribonucleotide reductase
activity and subsequently promotes DNA damage [26],
and with UCN-01, a CHK1 inhibitor [27] that prevents
cell cycle arrest leading to deficient DNA repair.
To determine whether gemcitabine is an effective inhi-
bitor of TNBC cell proliferation as a single agent, MDA-
MB-231 and M6 cells were tested in triplicate with at
least eight different doses over a concentration range of
10 μM to 1 μM and assayed for changes in proliferation.
In keeping with a previous report [28], MDA-MB-231
cells were sensitive to gemcitabine with an average IC50
of 20 nM. M6 cells were also sensitive to gemcitabine
with an average IC50 of 3.9 nM. To determine whether
UCN-01 is an effective inhibitor of TNBC cell prolifera-
tion as a single agent, MDA-MB-231 and M6 cells were
treated with UCN-01 with at least eight doses over a con-
centration range of 50 rM to 1 μM and assayed for inhi-
bition of proliferation. MDA-MB-231 and M6 cells
treated with UCN-01 have average IC50 values of 173 nM
and 22 nM, respectively.
To determine whether combination treatment of gem-
citabine and UCN-01 resulted in a greater inhibition of
proliferation than either single agent, MDA-MB-231
(Figure 3A) and M6 cells (Figure 3B) were treated with
gemcitabine and UCN-01 either alone or in combination
at sub IC50 concentrations and proliferation was mea-
sured over three days. Compared to MDA-MB-231 cells
treated with vehicle, treatment with 10 nM gemcitabine
alone did not significantly reduce cell proliferation over
three days. Cells treated with 150 nM UCN-01 signifi-
cantly reduced proliferation by day three. However,
MDA-MB-231 cells treated with both drugs in combina-
tion showed the greatest inhibition of proliferation in
comparison to vehicle-treated cells on days two and
three. Since UCN-01 exerts a greater inhibitory effect
than gemcitabine treatment at these concentrations, a
comparison between UCN-01 and the combination treat-
ment determined that the dual treatment inhibits growth
more than UCN-01 alone on days two and three. M6
cells were also significantly growth inhibited by UCN-01,
gemcitabine (P = 0.02 for days one and three), and by
combination dosing with gemcitabine and UCN-01.
Gemcitabine and UCN-01 inhibit TNBC cell growth
synergistically
To determine whether the interaction of gemcitabine and
UCN-01 was synergistic or merely additive, the interac-
tions were evaluated by the Chou-Talalay CI method
[24]. In this method, a CI <1 represents synergism,
whereas a CI = 1 represents an additive effect and a CI
>1 represents antagonism. The CIs in all combination
treatments were less than 1 [see Additional file 2,
Table S2A], confirming that treatment with gemcitabine
and UCN-01 had a synergistic cytotoxic effect. Likewise,
with the M6 cells the combination treatment inhibited
proliferation more potently than either drug alone
(CI <1, Additional file 2, Table S2B).
To confirm that the effects of UCN-01 are related to
CHK1 inactivation, cells were also dosed alone and in
combination with sub IC50 concentrations of gemcitabine
and AZD 7762, an ATP-competitive checkpoint kinase
inhibitor [11] , and assayed for proliferation (Figure 3C
and 3D). Similarly, MDA-MB-231 (IC50 for AZD 7762 =
120 nM) and M6 (IC50 for AZD 7762 = 36 nM) cells
were growth inhibited when treated with gemcitabine
and this CHK1 inhibitor, suggesting that subIC50 dosing
of drugs that target RRM1/RRM2 and CHK1 could be an
effective therapy regimen for TNBC.
It has been established that gemcitabine exerts anti-
tumor activity through two different mechanisms. Gem-
citabine inhibits RRM1 and RRM2 leading to inhibition
of nucleoside synthesis and DNA replication; it can also
be directly incorporated into replicating DNA leading to
the termination of DNA strand synthesis. To test
whether CHK1 inhibition worked synergistically with
another chemotherapeutic agent that damages DNA
through cross-linking, we performed similar experiments
using a combination of UCN-01 and cisplatin. Interest-
ingly, we did not observe a synergistic effect using this
Table 1 Z-scores of top gene hits for siRNA screen in
MDA-MB231 cells.
MB231 (screen 1) MB231 (screen 2) Hs578T MCF10A
ANLN -3.275 -2.657 -2.139 -2.230
CHEK1 -2.766 -2.441 -4.719 -0.218
KIF11 -2.475 -2.231 -3.832 -2.770
RRM1 -2.637 -2.347 -2.053 -0.955
RRM2 -3.647 -2.915 -2.518 -1.348
TPX2 -1.932 -1.697 -3.864 -1.452
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drug combination with MDA-MB-231 cells (data not
shown).
Combination therapy increases DNA damage associated
with inhibition of cell cycle progression
To interrogate how the combination treatment enhances
cell death, MDA-MB-231 cells were treated with gemci-
tabine and UCN-01 individually, and in combination,
and harvested for protein 24 hours later (Figure 4A).
Immunoblot analyses revealed that DNA damage, as
determined by phos-gamma-H2AX and phos-CHK1
expression, was minimally induced by gemcitabine.
However, treatment with UCN-01 as a single agent
resulted in increased DNA damage, which was further
increased when UCN-01 was given in combination with
gemcitabine. Total CHK1 protein expression was reduced
with UCN-01 and combination treatment at 24 hours. As
Cyclin A protein expression is highest in S-phase and
decreases with progression through the cycle, cell cycle
progression was stalled in S-phase by gemcitabine, as
demonstrated by the accumulation of Cyclin A protein
compared to control treated cells. However, cells treated
with UCN-01 alone or in combination with gemcitabine
exhibited reduced Cyclin A protein expression compared
to control-treated cells indicating cell cycle progression
through G2/M. BrdU incorporation into proliferating
MDA-MB-231 cells 24 hours after drug treatment
revealed that cell cycle progression was disrupted by all
drug treatments. In 79% of the cells treated with gemcita-
bine alone there was a dramatic increase in the S phase
component of the cell cycle (79%) compared to vehicle
treated cells (40%) at 24 hours. UCN-01 promotes cell
cycle progression at the G2/M checkpoint resulting in an
approximately two-fold decrease in the G2/M compo-
nent and a 50% increase in the G1 fraction (54%) com-
pared to vehicle treated cells (37%). Fifty-four percent of
the cells treated with both drugs were in the G1 fraction
and a significant, approximately three-fold increase in the
Figure 3 Combination therapy with CHK1 inhibitors and gemcitabine inhibits proliferation in TNBC cells. MDA-MB-231 (A, C) and M6 (B,
D) cells were treated with agents on day 0 and proliferation was measured on days indicated. MDA-MB-231 cells (gemcitabine 10 nM; UCN-01
150 nM), (gemcitabine10 nM; AZD 7762 200 nM). M6 cells (gemcitabine 4 nM; UCN-01 20 nM) (gemcitabine 4 nM; AZD 7762 30 nM). Results in
B and D are from one experiment thus Gem treatment and vehicle are the same in both panels. P-value based upon change from vehicle
treatment (letters only) and from single agent to combination treatment (line and letter) (A ≤ 0.01, B ≤ 0.005, C ≤ 0.001, D ≤ 0.0005).
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sub-G1 fraction of cells (14%) was observed compared to
UCN-01 alone (4%) (gemcitibine - 2%; vehicle - 1%) sug-
gesting that a large portion of combination treated cells
were undergoing cell death (Figure 4B).
To determine whether the combination therapy
increased apoptosis, MDA-MB-231 cells were treated
with the drugs and assayed for apoptosis by Annexin V-
FITC/7-AAD staining at 48 hours. Annexin V-FITC posi-
tive/7-AAD negative (early apoptosis) and Annexin V
positive/7-AAD positive (late apoptosis) labeling further
supported the finding that combination dosing of gemci-
tabine and UCN-01 enhanced cell death at subIC50 con-
centrations of the individual drugs (Figures 4C and 4D).
Other triple negative cell lines respond to the
combination treatment
The response of the MDA-MB-231 cell line to the gemci-
tabine and CHK1 inhibitor combination therapy supports
the idea that RRM1 and 2 and CHK1 are good targets for
triple negative tumors that overexpress these genes. To
determine whether other triple negative cell lines
respond to the gemcitabine-CHK inhibitor combination
treatment, cell lines BT-549, HCC 1187, and SUM 159
were tested. As described previously, cells were first trea-
ted with gemcitabine, UCN-01 or AZD 7762 over a dose
range to determine the IC50 concentrations of the single
agents (Table 2). The three cells lines were then treated
Figure 4 Combination therapy with UCN-01 and gemcitabine induces DNA damage and apoptosis in TNBC cells. (A) Protein samples
were collected 24 hours after drug treatment to detect changes in DNA damage (gamma-H2AX), checkpoint activation (phos-CHK1 andtTotal
CHK1) and cell cycle progression (Cyclin A) by immunoblot analysis. (B) Cell cycle changes were assessed by BrdU-labeling and propidium iodide
staining 24 hour after drug treatment. (C) Percentage of cells at 48 hours in early apoptosis (Annexin V +/7-AAD-) and late apoptosis (Annexin V
+/7-AAD+) with representative data (D). MDA-MB-231 cells (gemcitabine 10 nM; UCN-01 150 nM), M6 cells (gemcitabine 4 nM; UCN-01 20 nM).
P-value based upon change from vehicle treatment (A ≤ 0.01, B ≤ 0.005, C ≤ 0.001, D ≤ 0.0005).
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with sub IC50 concentrations alone and in combination
with the agents as noted previously. Proliferation of all
three cell lines was significantly inhibited by the combi-
nation treatments (Figure 5A-C). The combination treat-
ments were synergistic [see Additional file 2, Tables S2C-
E]. Moreover, the combination treatment increased the
level of apoptosis as measured on day two by a Caspase
3/7 assay [see Additional file 3, Figure S1A-C].
In addition, to determine whether the non-tumorigenic
human MCF-10A cell line and the ER+ MCF-7 tumori-
genic cell line also responded to this combination therapy,
IC50 concentrations were determined and cells were trea-
ted with <IC50 concentrations of the drugs as described
above. Combination therapy did inhibit the proliferation
of both of these cell lines more than that observed for
each drug alone [see Additional file 4, Figure S2. This is
not necessarily surprising given the mechanism of action
of these agents and the fact that these cell lines have been
selected to replicate relatively rapidly under tissue culture
conditions. Inhibition of the cell cycle checkpoint with the
induction of DNA damage in rapidly dividing cells would
lead to inhibition of cell growth and apoptosis. However,
unlike the response of the TNBC cells to the combination
therapy where there was overwhelming cell death, the
combination therapy treatment of MCF10A and MCF7
cells resulted in an initial reduction in cell numbers, but a
gradual recovery of cell growth over three days.
Expression of CHK1, RRM1 and RRM2 is not correlated
with p53 or Rb status
Since the gene signature we used in this study is in large
part related to the loss of p53 and Rb functions which are
typically lost in TNBC, we determined whether there was
a correlation between loss of p53 or Rb function and
expression of CHK1 or RRM1/2 in the microarray data of
the panel of 51 cell lines (including MCF10A and
MCF12A) reported by Neve et al. according to their
known p53 status. Cell lines were separated into two
groups dependent upon whether they harbor wild-type or
mutated/deleted p53. We found no statistical difference in
RRM1 or CHEK1 gene expression in cells with wild type
or mutated p53 protein (unpaired two-tailed t-test,
P = 0.456 for CHEK1 and 0.887 for RRM1). Pearson’s cor-
relation analysis of RRM1 or RRM2 or CHEK1 gene
expression was performed in association with Rb gene
expression or its regulator CDKN21 (p16 CDK inhibitor).
Table 2 IC50 Concentrations for other human triple
negative breast cancer cell lines.
BT- 549 SUM 159 HCC 1187
Gemcitabine 13.5 nM 5.27 nM 17.1 nM
UCN-01 160.8 nM 116.4 nM 230.5 nM
AZD 7762 275.2 nM 509.1 nM 307.7 nM
Figure 5 Combination therapy with CHK1 inhibitors and
gemcitabine inhibits proliferation in TNBC cells. BT-549 (A), SUM
159 (B) and HCC 1187 (C) cells were treated with agents on day 0
and proliferation was measured on days indicated. BT-549 cells
(gemcitabine 10 nM; UCN-01 100 nM; AZD 7762 150 nM). SUM 159
(gemcitabine 4 nM; UCN-01 80 nM; AZD 7762 300 nM). HCC 1187
(gemcitabine 10 nM; UCN-01 150 nM; AZD 7762 200 nM). P-value
based upon change from vehicle treatment (letters only) and from
single agent to combination treatment (line and letter; day three
only) (A ≤ 0.01, B ≤ 0.005, C ≤ 0.001, D ≤ 0.0005).
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We also did not find a correlation between expression of
Rb or p16 and any these genes. The correlation coeffi-
cients were ranging from 8E-5 to 0.057.
Combination therapy of gemcitabine with UCN-01
inhibits growth of TNBC tumor xenografts
To determine whether gemcitabine and UCN-01 inhibits
growth of triple negative breast tumors in vivo, we uti-
lized two mouse models, the C3(1)/Tag mouse mammary
tumor transplant model (previously established in our
lab) and the MDA-MB-231 human tumor xenograft
model. Freshly isolated 1 mm3 tumor fragments were
excised from C3(1)/Tag transgenic mice or MDA-MB-
231 tumor xenograft bearing mice and transplanted into
the mammary glands of SCID mice. Once tumors grew
to approximately 125 mm3 about eight to ten days later,
mice were dosed with gemcitabine by IP injection on a
Q4Dx3 schedule or UCN-01 by IV injection on a Q8Hx2
schedule repeated every other day for six days. Initial
screening to establish dose ranges revealed that both
models are sensitive to gemcitabine with tumor inhibi-
tion at doses greater than 40 mg/kg. However, both mod-
els had poor tumor sensitivity to UCN-01 at doses of 4.5
and 6.67 mg/kg (data not shown).
To determine whether combination treatment of UCN-
01 and gemcitabine reduced tumor growth better than
gemcitabine alone, SCID mice with MDA-MB-231 tumor
xenografts were treated seven days after tumor implanta-
tion with vehicle, 5 mg/kg gemcitabine, 6 mg/kg UCN-
01, or a combination of both on a Q4Dx3 schedule. Gem-
citabine was delivered first by IP injection to induce DNA
damage and UCN-01 was delivered 24 hours later by IV
injection on a Q6Hx2 schedule to block DNA damage
repair. MDA-MB-231 tumor growth, measured twice
weekly, was not affected by treatment with vehicle or
UCN-01 as a single agent, but it was significantly inhib-
ited by treatment with gemcitabine alone (Figure 6A).
Combination treatment initially resulted in a modest
further inhibition of tumor growth compared to gemcita-
bine treatment alone, which was not sustained once ther-
apy was discontinued. (Figure 6A inset)
SCID mice with C3(1)/Tag tumor fragments were
dosed 12 days after transplantation with 20 mg/kg gemci-
tabine, 4.5 mg/kg UCN-01, or the drug combination on a
Q4Dx3 schedule. Gemcitabine was delivered first and
UCN-01 was delivered eight hours later on a Q6Hx2
schedule. Mice treated with vehicle showed exponential
growth over eight days (Figure 6B). Treatment with
UCN-01 did not inhibit tumor growth while gemcitabine
significantly reduced tumor growth. Mice treated with
both UCN-01 and gemcitabine showed remarkable inhi-
bition in tumor growth up to the end of the study period
at day 30 compared to the single agent treatments.
Discussion
This study has explored the functional significance of
genes within a previously described Tag expression signa-
ture, which includes many genes dysregulated through
the loss of p53 and Rb function and which is highly
expressed in human TNBC [8]. Based upon an analysis of
gene expression of 51 human breast cancer cell lines, we
identified MDA-MB-231 cells as a TNBC cell line that
robustly expresses the Tag signature. We designed a
human siRNA library to knock-down the up-regulated
genes in the Tag signature and utilized the high-through-
put readout of proliferation changes to efficiently screen
for genes whose loss of function significantly reduced cell
growth. The identification of RRM1, RRM2 and CHK1 as
key regulators of TNBC growth suggests that this screen-
ing method is an effective tool for identifying potential
drugable targets. Our further validation of these candi-
dates in other cell lines and xenograft models suggests
that we have identified a potentially useful drug combina-
tion, gemcitabine and a CHK1 inhibitor, for treatment of
TNBC. While some BrCa patients are treated with gem-
citabine, the addition of a CHK1 inhibitor may offer the
possibility of achieving a better therapeutic response or
an improved response using a lower dose of gemcitabine
for patients who may be more susceptible to the side
effects of gemcitabine.
A major concern for novel drug therapies is acquired
drug resistance and it is thought that combination thera-
pies are more effective than single agents [29]. We utilized
the availability of small molecule inhibitors of CHK1
(UCN-01 and AZD 7762) and RRM1 and RRM2 (gemcita-
bine), to test the efficacy of these compounds on human
TNBC cells as well as the M6 cell line derived from the
C3(1)/Tag mammary tumors. By inhibiting both CHK1
and ribonucleotide reductase, we saw a superior inhibition
of proliferation in vitro and tumor growth in vivo. We
hypothesized that the inhibition of CHK1 in the context of
inducing DNA damage through the disruption of RRM1
and RRM2 function by gemcitabine could significantly
augment the killing capacity of gemcitabine. Our in vitro
results indicated that this was the case. The combination
treatment of UCN-01 and gemcitabine led to both a
reduction of CyclinA - indicating a loss of stalling in S-
phase and movement through the G2/M checkpoint and
increased DNA damage as reported by an increase in
phospho-gamma-H2AX expression. Fluorescence acti-
vated cell sorting (FACS) analysis further revealed that the
combination therapy drove cells through the G2/M check-
point and induced significant apoptosis. We also demon-
strated that by combining UCN-01 with gemcitabine, a
lower dose of gemcitabine could be used to kill the tumor
cells, which has translatable potential to the clinic. Our in
vivo results demonstrated that inhibition of CHK1 alone
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did not have a striking effect on tumor development,
although gemcitabine was quite growth inhibitory to the
tumors. In fact, MDA-MB-231 tumor growth was almost
completely abrogated by gemcitabine alone. During the
course of actual drug treatment, the combination inhibited
tumor growth better than gemcitabine alone. However,
once treatment was discontinued, the effect was not as
obvious. This suggests that alternative dosing schedules
may improve the efficacy of this combination therapy.
The value of genetically-engineered mouse models of
human cancer for preclinical studies has been demon-
strated for particular cancer models and drugs [30].
Figure 6 In vivo response of TNBC tumors to agents that target CHK1, RRM1 and RRM2. (A) SCID mice with MDA-MB-231 tumor
xenografts were treated seven days after implantation with vehicle, 5 mg/kg gemcitabine, 6 mg/kg UCN-01, or a combination of both on a
Q4Dx3 schedule. Gemcitabine was delivered first by IP injection and UCN-01 was delivered 24 hours later by IV injection on a Q6Hx2. Note: Inset
graph highlights days 7 to 21. During this period, mice treated with the combination therapy had slower growing tumors than those treated
only with gemcitabine. (B) SCID mice with C3(1)Tag tumor transplants were dosed 12 days after transplantation with 20 mg/kg gemcitabine, 4.5
mg/kg UCN-01, or the drug combination on a Q4Dx3 schedule. Gemcitabine was delivered first and UCN-01 was delivered eight hours later on
a Q6Hx2 schedule.
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Based upon this study, the C3(1)/Tag model exhibits
important molecular similarities to human TNBC that
can be used to test targeted therapies. An important
advantage of using this transgenic model is that studies
can be performed in animals with an intact immune sys-
tem unlike model systems that use human xenografts.
Given the importance of the immune system in regulat-
ing tumor development, this model system will allow for
novel combination therapies that may inhibit particular
targets critical to the growth and survival of TNBC
along with anti-cancer therapies that alter the immune
response. We have recently developed a novel, syngeneic
transplantable model system for C3(1)/Tag tumors that
will allow for the more rapid screening of therapies
using this model of TNBC (manuscript in preparation).
Our findings correlate well with a recent report that
identified CHK1 as being over-expressed in TNBCs and
that p53 expression does not directly effect CHK1
expression [31] suggesting that CHK1 is a valid TNBC
target, distinct from other non-tumor cells. Our analyses
did not find a correlation between loss of p53 or Rb
function and increased expression of CHK1 or RRM1/2
suggesting that the increased expression is not a direct
result of the loss of these tumor suppressor activities.
Although we used UCN-01 as a CHK1 inhibitor for
most of our studies, it is known that UCN-01 binds to
human plasma proteins [32,33] and thus has not been
successful in the clinic. There are several other CHK1
inhibitors in development that are being tested in clinical
trials [25] to determine whether they have better bio-
availability and target specificity. One such agent is AZD
7762, which we used to confirm our in vitro results but
did not have ample supply available for animal studies.
Gemcitabine and CHK1 inhibitor (AZD 7762) are cur-
rently being tested in clinical trials as a combination ther-
apy for late stage cancers. The results of our study
suggest that this combination may be quite efficacious
for patients with TNBC, or other patients whose tumors
overexpress CHK1, RRM1 and RRM2. A Phase I clinical
trial using the combination of UCN-01 and a topoisome-
rase inhibitor that also induces DNA damage has recently
been reported for resistant solid tumor malignancies with
suggestion of a positive response in two patients with
TNBC [34].
It is possible that this combination therapy may be of
value in other subtypes of BrCa which will need to be
elucidated in future studies and where predictive biomar-
kers would identify patients who may respond to this
therapy. It is also possible that baseline levels of CHK1
expression may not be the sole determining factor for
efficacy of a CHK1 inhibitor, but rather the response of
CHK1 expression in a tumor to a chemotherapeutic
agent may be an important factor in defining the useful-
ness of a CHK1 inhibitor. Thus, tumors with low baseline
levels of CHK1 may still benefit from a CHK1 inhibitor if
CHK1 becomes elevated in response to a chemothera-
peutic agent. This possibility should be explored in future
studies.
Conclusions
In summary, the functional analysis of genes contained
within an expression signature originally identified
through genomic cross-species analysis identified CHK1,
RRM1 and RRM2 as potential targets for therapy. Com-
bination therapy that inhibits both of these pathways
showed a strong synergistic effect and may have transla-
tional value in treating human TNBC patients. Impor-
tantly, using relevant models of TNBC, we demonstrate
in vivo that this combination therapy does result in a
greater anti-tumor effect than either agent alone. The
results of this study demonstrate that a ‘subtype specific’
gene expression signature, first identified through geno-
mic analyses of genetically-engineered mouse (GEM)
models of human cancer, can be valuable to rationally
screen for drug targets and combination therapies. The
validation of therapies in a standard xenograft model
and a highly relevant GEM model of TNBC provides
further support for considering this combination therapy
in human clinical trials.
Additional material
Additional file 1: Table S1. Custom siRNA oligo pools used for
screening tumor cells.
Additional file 2: Table S2. Combination Index data for drug synergy in
triple negative cells.
Additional file 3: Figure S1. Combination therapy with Chk1 inhibitors
and gemcitabine increases apoptosis in TNBC cells. BT-549 (A), SUM 159
(B) and HCC 1187 (C) cells were treated with agents on day 0 and
apoptosis was measured by Caspase 3/7 assay on day two. BT-549 cells
(gemcitabine 10 nM; UCN-01 100 nM; AZD 7762 150 nM). SUM 159
(gemcitabine 4 nM; UCN-01 80 nM; AZD 7762 300 nM). HCC 1187
(gemcitabine 10 nM; UCN-01 150 nM; AZD 7762 200 nM). P-value based
upon change from vehicle treatment (letters only) and from single agent
to combination treatment (line and letter) (A ≤ 0.01, B ≤ 0.005, C ≤
0.001, D ≤ 0.0005)
Additional file 4: Figure S2. Combination therapy in normal and ER+
breast cancer cells reduces proliferation. The non-tumorigenic mammary
cell line MCF10A (A) and the ER+ breast cancer cell line MCF-7 (B) were
treated with individual agents or combination on day 0 and proliferation
was measured by MTS assay on days indicated. MCF10A cells
(gemcitabine 4 nM; UCN-01 20 nM), (gemcitabine 4 nM; AZD 7762 300
nM). MCF-7 cells (gemcitabine 8 nM; UCN-01 25 nM), (gemcitabine 8 nM;
AZD 7762 50 nM). P-value based on change from vehicle treatment for
all days (letters only) and from single agent to combination treatment,
day three only (line with letter) (A ≤ 0.01, B ≤ 0.005, C ≤ 0.001, D ≤
0.0005).
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